Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center-Reference-Cited by-同舟云学术

Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center

Published:2020-10-01 Issue:10 Volume:156 Page:1079
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Yu Zizi¹,Dee Edward Christopher¹,Bach Daniel Q.²,Mostaghimi Arash³,LeBoeuf Nicole R.³⁴

Affiliation:

1. Harvard Medical School, Boston, Massachusetts

2. Division of Dermatology, University of California, Los Angeles Medical Center, Santa Monica

3. Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

4. Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women’s Cancer Center, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Dermatology

Link

https://jamanetwork.com/journals/jamadermatology/articlepdf/2767661/jamadermatology_yu_2020_oi_200035_1602515648.93353.pdf

Reference17 articles.

1. Cetuximab for the treatment of colorectal cancer.;Jonker;N Engl J Med,2007

2. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.;Bonner;Lancet Oncol,2010

3. Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review.;Lacouture;Clin Colorectal Cancer,2018

4. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective: impact on health-related quality of life and implications for clinical management of psychological sequelae.;Wagner;Oncology (Williston Park),2007

5. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.;Eilers;J Natl Cancer Inst,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus of the Taiwanese dermatological association and Taiwan Lung Cancer Society on the prevention and management of tyrosine kinase inhibitor-related skin toxicities in patients with non-small cell lung cancer: An updated version incorporating Taiwanese treatment experience;Journal of the Formosan Medical Association;2024-08

2. CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events;Holistic Integrative Oncology;2024-06-28

3. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors;Journal of Cutaneous Medicine and Surgery;2023-11

4. Cutaneous immune‐related adverse events from immune checkpoint inhibitor therapy: Moving beyond “maculopapular rash”;Immunological Reviews;2023-08-15

5. Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis;Pharmaceuticals;2023-06-27